ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Ono bolsters sales force for cancer drugs

OSAKA -- Ono Pharmaceutical has redeployed a significant portion of its sales force to the cancer battlefront to promote a new cancer immunity drug.

     Rather than attacking cancer directly, Opdivo is an antibody that works by enhancing the ability of the immune system to recognize and attack cancer cells. It was approved in Japan for the treatment of melanoma in 2014, and also for lung cancer this past December.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more